To cite this article: Aldea-Ramos, N. (2022). Methodological elements for the comparative analysis of the first wave of the Covid-19 epidemic in France, Italy, and Spain. Investigaciones Geográficas, (77), 37-55. https://doi.org/10.14198/INGEO.19060

Methodological elements for the comparative analysis of the first wave of the Covid-19 epidemic in France, Italy, and Spain

Elementos metodológicos para el análisis comparativo de la primera ola de la epidemia de Covid-19 en Francia, Italia y España

Néstor Aldea-Ramos¹

Abstract

The three European countries included in the northwest littoral of the Mediterranean region -Italy, France and Spain – reported their first cases of the SARS-CoV-2 coronavirus early in 2020. The subsequent epidemic strongly impacted these countries, challenging the healthcare systems efficiency, and the capacity and transparency of their public statistics structures. Because public statistics were not fully adapted to such a new health situation, the available official data could not wholly describe the epidemic correctly. This paper developed an indicator derived from the prevalence of SARS-CoV-2 aiming to describe the time and spatial dynamics of the epidemic. Although the analysis was not applied to France due to the lack of data available, the comparative analysis among Spain and Italy highlighted some similarities and certain divergences, partially attributable to the features of each country's national demographic patterns and the peculiarities of applied health protocols. Finally, mortality during the first wave of the epidemic has been analysed for the three countries, demonstrating higher mortality index in Spain, although the reported number of SARS-CoV-2 declared deaths does not explain a portion of this mortality excess.

Keywords: Covid-19; epidemiology; demography; mortality; health.

Resumen

España— notificaron sus primeros casos del nuevo coronavirus SARS-CoV-2 al comienzo del año 2020. La consiguiente epidemia impactó intensamente estos países, desafiando la eficiencia de sus sistemas de atención sanitaria, así como la capacidad y transparencia de sus estructuras de estadística pública. Dado que la estadística pública no estaba completamente adaptada a la nueva situación sanitaria, los datos oficiales disponibles no pudieron describir en su totalidad la epidemia de manera correcta. Esta contribución ha desarrollado un indicador derivado de la prevalencia del SARS-CoV-2 con el objetivo de analizar la dinámica espacio-temporal de la epidemia. Aunque el análisis no se ha aplicado en Francia debido a la falta de datos, el análisis comparativo entre España e Italia destaca ciertas similitudes y algunas diferencias, parcialmente atribuibles a las características demográficas propias de cada país, así como a los protocolos sanitarios puestos en marcha. Por último, la mortalidad durante la primera ola de la epidemia en los tres países ha sido analizada, mostrando una mayor tasa de mortalidad en España, si bien parte de ese exceso de mortalidad no se explica por el número de defunciones declaradas por causa de SARS-CoV-2.

Palabras clave: Covid-19; epidemiología; demografía; mortalidad; salud.

Received: 02/15/2021.

Published: 01/26/2022 (in press: 09/24/2021). This work is published under a license Creative Commons Attribution 4.0 International License

¹ Institute of Demography, University Paris 1 Panthéon-Sorbonne (Paris, France). Nestor.Aldea.Ramos@gmail.com

1. Introduction

The Covid-19 epidemic has entailed, since its outbreak, a public health concern and a major mortality event in France, Italy and Spain, the countries forming the north-west littoral of the Mediterranean. In those countries, the first detected cases of the disease took place early in 2020, as noted by Spiteri, *et al.* (2020) and Bernard Stoecklin, *et al.* (2020).

Since, their offices for public statistics have published different data concerning the epidemiological features of the epidemic, mainly the number of deaths and identified cases, as well as some data about the patients in hospitals and intensive care services. The amount and quality of available official public data increases with time and, for the first wave of the epidemic (until summer 2020), available data remains poor and inaccurate, making the analysis of the epidemic difficult.

In Italy, the data published by *Protezione Civile* since the beginning of the epidemic includes the daily number of new Covid-19 cases by region and province, as well as the number of deaths officially attributed to Covid-19 by region. In Spain, the *Carlos III* Health Institute publishes the number of new Covid-19 cases by province, and the Ministry of Health publishes the number of daily fatalities attributed to Covid-19 by region. In the case of France, the number of Covid-19 cases by department, published by *Santé Publique France*, is only available starting from May 13. In addition, the daily number of hospital deaths attributed to Covid-19 by department is published since the beginning of the epidemic. However, fatalities taking place in nursing homes are only published at a national level and bit by bit, by the Ministry of Health (see Appendix 1 for details on data sources).

Besides, a serological study named ENECOVID has been performed in Spain in an effort to stablish the proportion of the population having Covid-19 antibodies. Though controversial in some aspects, as shown by Hoffmann & Wolf (2020), the results of the first wave of this study, published by Pollán, *et al.* (2020), suggest that the number of detected cases in the country during the first wave of the epidemic enormously underestimated the actual number of people infected by a factor around 10. Also concerning the first wave of the epidemic, a great underestimation of the number of infections has been estimated by Roques, Bonnefon, Baudrot, Soubeyrand & Berestycki (2020) for the case of France and measured by Stefanelli, *et al.* (2020) for a specific area in northeastern Italy.

This important underestimation can also apply to other countries during the first wave, and the relation between confirmed cases and actual infections is not well known, as it mostly depends on the screening strategies that have been put in place in each country. Therefore, the actual number of people infected by Covid-19 remains unknown and the confirmed cases data cannot be, in any case, a substitute of this magnitude.

Consequently, a classical description of the disease by its incidence, prevalence and lethality must be dismissed, and those indicators must only be used in restricted ways. In this context, the production of indicators that are able to describe the dynamics and mortality of the epidemic, while being little dependent on the accuracy of public data about Covid-19 cases and fatalities, is crucial.

Concerning the number of Covid-19 infections, the inaccuracy of public data makes it unable to describe properly the epidemic by itself, and the potential screening differences between countries for this period make any international comparison based on this data inaccurate. Moreover, the effect of the lockdown policies implemented during the spring 2020 in Italy, France and Spain cannot be apprehended by this row data, as the study of the spatial spreading of the virus needs a more complex indicator.

Proposed indicators for the description of the mortality during the epidemic are often strictly dependent on the accuracy of data in the allocation of the cause of death as Covid-19. If we could assume a certain accuracy in the assignation of Covid-19 as the death cause when it takes place in a hospital, this accuracy can be lower for deaths taking place elsewhere. In addition, the three countries under study have employed different methods when assigning deaths to Covid-19, depending on if the person has been tested for the coronavirus and how, as reported by The Health System Response Monitor (HRSM) (2020). In France, the WHO guidelines for the definition of Covid-19 deaths have been followed, considering any "clinically confirmed or probable Covid-19 case" and therefore "not dependent on the availability of a laboratory test" (HRSM, 2020). By contrast, Spain and Italy would only consider a Covid-19 death under a positive laboratory test (HRSM, 2020). Thus, a clear analysis of Covid-19 deaths will only be possible with individual mortality data including a cause, which is not yet available for this first wave of the epidemic.

This paper will then focus on the first wave of the epidemic in Italy, France and Spain, lasting until summer 2020. The first purpose, concerning the dynamics of the epidemic, is to define an indicator being able to describe properly the spatial and time evolution of the epidemic, being also suitable for comparing this evolution in different countries, which is a key to understanding the epidemic, as highlighted by Pearce, Lawlor & Brickley (2020). There is a limitation to this approach: the necessary regional data for the description of the dynamics of the epidemic is not available in France for the first wave, as *Santé Publique France* has only published regional data on cases starting from May 13, 2020. Consequently, this analysis, as it is detailed in 2.1, will be here limited to Italy and Spain.

Moreover, a clear description of the mortality during the epidemic is here intended using only allcause non-individual mortality data by age in the three countries, collected and published by the Human Mortality Database (see Appendix 1 on data sources).

2. Methodology

The dynamics of the epidemic will be analyzed here for the first wave of the Covid-19 epidemic. Considering the three countries under study, this period starts in February 2020 and lasts until the summer. The choice of such a short period instead of the whole epidemic rely on the considerable evolution of testing policies and its efficiency: we can assume that the number of new Covid-19 cases gets closer and closer to the actual number of infections, and therefore the first and the second wave should be studied separately when using Covid-19 cases as data.

In a general and rough way, a disease spreading could be described with only four parameters:

- 1. its prevalence, as a ratio of the number of alive patients to the population exposed to risk;
- 2. its incidence, as a ratio of the new cases of the disease recorded during a certain period of time to the risk-exposed population;
- 3. its lethality, as a proportion of those who died in a specific cohort of patients;
- 4. the mean length of the disease, starting from the infection until death or convalescence.

In the case of an infectious, transmissible and non-fatally mortal disease providing immunity, two other parameters need to be taken into consideration: 1) the duration of immunity (and, subsequently, the period of virus mutation); and 2) the transmissibility of the infection from a sick individual to a healthy, vulnerable one.

However, given the type and accuracy of public data on the epidemic, some of those parameters are unknown or cannot be computed, as it will be discussed below, forcing us to an alternative description of the Covid-19 dynamics and mortality.

2.1. The dynamics of the epidemic

The state of propagation of a disease is often described by its incidence and prevalence. The incidence of a disease in a population *x* at a time *t* for a period τ is defined as the proportion between the number of new cases *c* of the disease during the period τ immediately prior to *t* and the size of the population.

$$I_{x}(t,\tau) = \frac{1}{P_{x}(t)} \cdot \int_{t-\tau}^{t} c_{x}(T) dT$$
(1)

Statistically, the number of new cases is given by day, so the continuous equation (1) becomes then discrete.

$$I_{x}(t,\tau) = \frac{1}{P_{x}(t)} \cdot \sum_{i=t-\tau}^{t} c_{x}(i)$$
(2)

This incidence can be written, alternatively, as the mean number of daily cases during the period τ multiplied by the period length:

$$I_{x}(t,\tau) = \frac{1}{P_{x}(t)} \cdot \tau \cdot \bar{c}(t-\tau,t)$$
(3)

As for prevalence, in its most used definition (*i.e.* point prevalence), it represents the proportion of a population suffering from the disease at a certain moment. However, this point prevalence is impossible

to measure or compute in the case of Covid-19, as the duration of the disease seems extremely variable and there is not available data about the recovery of all reported cases. A different meaning of prevalence must be thus adopted, in order to match with the current knowledge of the disease and the available data.

Two alternative definitions of prevalence exist: period prevalence (*i.e.* proportion of a population having suffered from the disease at any moment of a given period) and lifetime prevalence (that is, proportion of a population having suffered from the disease at any moment of their lives). Given the fact that our period of study starts at the very first Covid-19 case reported, and that there is no evidence of an individual having contracted the disease twice during the first wave, those two definitions become one and the same, and that is precisely what will be subsequently called prevalence. Hence, the prevalence of Covid-19 in a population x at a time t can be expressed – in terms of the sum of new daily cases – as:

$$Prev_{x}(t) = \frac{1}{P_{x}(t)} \sum_{i=0}^{t} c_{x}(i)$$
(4)

It is self-evident that equations (2) and (4) become the same when $\tau = t$, that is: the incidence of Covid-19 is equal to its prevalence when the former is set for a period beginning at the very first Covid-19 case reported in the population. Given the period on which this paper aims to focus (*i.e.* the first wave of the epidemic, until summer 2020), the irregularities and measure-induced fluctuations present in public data for that term could generate an immoderate, undesirable variability on incidence, if it is set for a short period. The cumulative character of prevalence makes it less likely to be affected by potential short-term variability in the time series of reported Covid-19 cases, and thus prevalence will be taken on as a more suitable indicator for this case.

However, as stated before, the different testing policies and strategies adopted for each population need to be taken into account when performing and using prevalence. This fact, alongside the evidence that a large part of Covid-19 infections has not been detected and reported as cases during the first wave, impose two constraints. Firstly, reported cases – and their corresponding incidence and prevalence – cannot fully describe the magnitude of the epidemic. In addition and consequently, prevalence itself cannot be the ground for any comparison between countries for this period.

The objective here is limited to the study of the spatial spread of the virus within a large population X (*e.g.* a country), here Italy, France and Spain. For that matter, prevalence data need to be available for k exhaustive, non-overlapping subpopulations (*e.g.* provinces, regions) such as $\{X_1 \dots X_k\} \subset X$. As the individuals within each subpopulation will not be distinguished, each subset or subpopulation X_i can be treated, in practice, as a sole element x_i with attributes P_{x_i} – its population size – and $Prev_{x_i}$ – its prevalence –, at any time. They can therefore be written as $\{x_1 \dots x_k\} \in X$.

With the purpose of avoiding leaning on the accuracy of the Covid-19 screening, the relative prevalence of a subpopulation x_i to the whole population X will be defined. The construction of this relative prevalence is based on the assumption that the accuracy of Covid-19 screening is comparable, to a large extent, in every subpopulation x_1 . This means that, if, in the subpopulation x_i , only a certain proportion of infections is diagnosed and reported as cases, that proportion will be similar for the rest of the subpopulations $\{x_2 \dots x_k\}$.

In practice, this assumption will be made for subpopulations within the same country, as testing policies can be considered rather homogenous inside that country. Accordingly, in this case, the population X will be that one of a country (here Italy, Spain or France) and x_i its corresponding administrative subpopulations (provinces or regions for Italy and Spain and departments or regions for France).

Therefore, the relative prevalence of a subpopulation x_i within a population (country) *X* can be expressed as:

$$RPrev_{\chi_i}(t) = \frac{Prev_{\chi_i}(t)}{Prev_{\chi}(t)}$$
(5)

This relative prevalence is thus equal to one for the population X itself. At this point, an indicator describing the spatial distribution of the epidemic within the territory of a country – population X– can be constructed from this relative prevalence. The use of the relative prevalence, added to the testing policies homogeneity hypothesis, will make this indicator independent of the screening

accuracy and hence suitable for a comparison of the spatial dynamics over time of the epidemic in different populations (*i.e.* countries).

The aforementioned indicator will be defined, for a population *X* and at an instant *t*, as:

$$S_X(t) = + \sqrt{\frac{1}{P_X(t)} \sum_{x_i \in X} P_{x_i}(t) \cdot \left(RPrev_{x_i}(t) - 1\right)^2}$$
(6)

This *S*, that will be also referred to as "spreading indicator", has the shape of a "weighted" standard deviation. Indeed, it expresses the standard deviation of each subpopulation's relative prevalence, weighted by the size of that subpopulation. It can thus be deducted that $S \ge 0$ and that, the smaller its value, the closer the relative prevalence's values of each subpopulation are. In the limit case, *S* could be equal to zero if every subpopulation has the same prevalence, that is, every relative prevalence is equal to one.

Yet, it is clear that this spreading indicator depends on how a territory is administratively divided and how its population is split within those divisions. Likely, the smaller the divisions, the higher *S* will be. Thus, *S* will be tested with two different levels of division – regions and provinces – in order to prove its validity beyond a specific segmentation of the territory or the population.

In practice, this method will only be applied for Italy and Spain, as the number of Covid-19 cases by region and department in France is only available starting from May 13, 2020 (SIDEP data on laboratory tests).

2.2. Mortality during the epidemic

Mortality will be studied for a period of twelve weeks covering the higher mortality term of the first wave of the epidemic. Those weeks are 11 to 22 (from March 9 to May 31, 2020) for Spain and France, and weeks 10 to 21 (from March 2 to May 24, 2020) for Italy.

As the actual number of people infected by Covid-19 is unknown, the lethality of the disease (*i.e.* number of deaths caused by Covid-19 divided by the number of people infected during a certain period) cannot be estimated. Therefore, fatalities derived from Covid-19 must be imperatively expressed by crude or specific mortality rates.

The number of deaths officially attributed to Covid-19 for an age group *A* of a population *X* within a period $T = [t_0, t_1]$ can be expressed as a sum of daily deaths *d*, and thus its corresponding specific mortality rate can be put as:

$$MR_{T,A,X}^{C19} = \frac{D_{T,A,X}^{C19}}{P_{T,A,X}} = \frac{\sum_{i=t_0}^{t_1} d_{i,A,X}^{C19}}{P_{T,A,X}}$$
(7)

As for the whole of mortality (all causes), the excess mortality – and its corresponding rate – will be here employed as a way to measure the impact of the first wave of the epidemic on mortality. Excess mortality for a certain period is defined as the difference between the observed and the expected deaths for that period. Considering variations of death rates and population negligible for the last five years in the three countries under consideration, the number of expected deaths in an age group *A* within a population *X* for a period *T* in 2020 can be reckoned as the mean of the past five years for that same period, that is:

$$D_{T,A,X}^{exp} = \frac{1}{5} \sum_{i=2015}^{2019} D_{T(i),A,X}^{obs}$$
(8)

Then, the excess mortality rate for that age group *A*, population *X* and period *T* will be:

$$EMR_{T,A,X} = \frac{D_{T,A,X}^{obs} - D_{T,A,X}^{exp}}{P_{T,A,X}}$$
(9)

Furthermore, the difference between the number of excess deaths and the number of deaths officially attributed to Covid-19 can be expressed by what will be – from this point on – referred to as "balance mortality". Its correspond rate for an age group *A*, population *X* and period *T* will be:

$$BMR_{T,A,X} = \frac{D_{T,A,X}^{obs} - D_{T,A,X}^{exp} - D_{T,A,X}^{C19}}{P_{T,A,X}}$$
(10)

However, the generalization to the whole population of the three mortality rates from equations (7), (9) and (10) (*i.e.* crude rates) could be misleading, as the three countries under consideration show moderate disparities in the age structure of their population. Given the great age gradient of general and Covid-19 mortality – as shown by Kaeuffer, *et al.* (2020), Giorgi Rossi, *et al.* (2020) and Working group for the surveillance and control of COVID-19 in Spain (2020) –, it is thus necessary to standardize mortality rates by age in order to avoid undesirable effects of different age structures.

Therefore, for a population *X* with *m* exhaustive, non-overlapping age groups $\{A_1 \dots A_m\}$ whose *m* corresponding proportions in a reference population *Y* are $\{q_1 \dots q_m\}$, any of the former mortality rates (MR^{C19}, EMR, BMR) can be standardized for the population *X* over the age structure of the population *Y* as follows:


$$SMR_{T,X} = \sum_{j=1}^{m} MR_{T,A(j),X} * q_j$$
 (11)

In practice, five age groups will be stablished for each population, in order to match the used data, from the Human Mortality Database (0-14, 15-64, 65-74, 75-84 and 85 or more years old). Furthermore, the structure by age of the population of Spain will be employed as the reference for the standardization.

3. Results

Eight out of 107 Italian provinces show a relative prevalence higher than 1.5 two weeks before the national lockdown [Figure 1A]. All of them are located in the North, and six of them close to the city of Milan. This number rises to twelve (combining for 11 % of the Italian population) on the first day of lockdown (March 9) and to seventeen provinces two weeks after the implementation of the lockdown (see Appendix 2 for details on prevalence by province). All those provinces are located in the northern part in the country and most of them are in the Lombardy and Emilia-Romagna regions.

Figure 1. Provinces with a relative prevalence higher than 1.5 in Italy (A) and Spain (B), two weeks before the lockdown, the first day of the lockdown and two weeks after the lockdown implementation





Own elaboration

In Spain, six out of fifty provinces show a relative prevalence above 1.5 two weeks before the national lockdown [Figure 1B]. Those are the provinces in the axis between the cities of Madrid and Vitoria. On the first day of lockdown (March 15), this number rises up to eleven provinces (combining for 21 % of the country population). Two weeks after the lockdown, one more province reaches a relative prevalence of 1.5. Thus, Spain shows a higher spatial spread of the virus than Italy in the weeks preceding and following the effective date of the lockdown.

The spreading indicator *S* describes properly the spatial evolution of the epidemic. In both Italy and Spain, the evolution of *S* follows the same pattern: the high values at the very beginning of the epidemic are followed by a stabilization of *S* due to lockdown policies. In summer, with the termination of those policies, *S* takes its decrease back as the second wave of the epidemic begins [Figures 2 and 3].

The success of lockdown policies in confining the epidemic within certain regions is shown by the stabilization of *S* following the implementation of those policies. This stabilization is well seen in both Spain ($S_{provinces} \in [0.704, 0.717]$ and $S_{regions} \in [0.631, 0.649]$ between April 15 and June 30) and Italy ($S_{provinces} \in [0.900, 0.933]$ and $S_{regions} \in [0.761, 0.807]$ between April 15 and July 31), where *S* even increases slightly from the beginning of May.





Source: Carlos III Health Institute. Own elaboration

As foreseen in the Methods section, *S* depends on the division of the territory and is higher for smaller divisions (*i.e.* provinces). Furthermore, this difference is higher in Italy, where twenty regions contain 101 provinces, than in Spain, where seventeen regions contain only fifty provinces plus two autonomous cities.

However, the dependence on the territorial division is limited, and *S* remains smaller in Spain for the whole period (as shown in Figure 1A and 1B), regardless of the territorial division under study [Figure 4]. This shows that, independently of the screening level in those two countries, the epidemic was geographically more spread in Spain that in Italy. Even if lockdown policies do stabilize *S*, the ratio of *S* between Italy and Spain increases slightly from April until the second wave, where the decay of *S* is greater in Italy, due to a more homogeneous distribution of the epidemic in the dawn of that second wave.




Figure 3. Evolution of the spreading indicator *S* (for regions and provinces) and the daily number of Covid-19 cases (15-day rolling average) in Italy between February and November 2020





Figure 4. Ratio of the spreading indicator S in Italy to S in Spain. By region and by province



3.1. Mortality during the epidemic

Limiting the analysis to the twelve weeks within the first wave (weeks 10 to 21 of 2020 for Italy and weeks 11 to 22 of 2020 for France and Spain), the three countries show a high excess mortality [Figure 5]. For this period, Italy presents 51,535 excess deaths (+35 % than expected), France shows 29,151 (+22 %) and Spain shows 48,850 (+52 %).

Besides, the addition of the number of official Covid-19 deaths to the number of expected deaths explains only partially the number of observed deaths. This difference, that have been called balance deaths, is high for Italy (18,785 deaths) and Spain (20,368 deaths), and almost inexistent in France (368 deaths).




Figure 5. Weekly expected deaths, observed deaths and sum of expected and reported Covid-19 deaths for Italy (weeks 10 to 21, 2020), France and Spain (weeks 11 to 22, 2020)

Sources: European Centre for Disease Prevention and Control, The Human Mortality Database. Own elaboration

This increase of the number of deaths in this period is extremely variable by age and, while all the three countries see the number of deaths decrease for people aged under 15, there are indicative increases for the rest of age categories [Table 1]. Excepting the youngest age category, it is Spain where the number of deaths increases the most for every other age category. For the population aged 85 and more, the increases are the vastest, and reach 68 % in Spain, 40 % in Italy and 30 % in France. In this last country, the increase is only indicative starting from 65 years old, while Italy and Spain do observe an increase of 15 % and 18 % respectively within the population aged between 15 and 64 years old.

Table 1. Relative increase (2020 vs. 2015-19) in total deaths by age group in Italy (weeks 10 to 21), France and Spain (weeks 11 to 22)

Age	0-14	15-64	65-74	75-84	85+	All ages
Italy	-15%	+15%	+35%	+35%	+40%	+35%
France	-13%	+3%	+26%	+18%	+30%	+22%
Spain	-34%	+18%	+46%	+47%	+68%	+52%

Own elaboration

The standardization over the structure by age of the population of Spain soothe the excess mortality rate and Covid-19 mortality rate for Italy [Table 2], by 13 and 14 %, respectively. This is due to Italy having an older population structure (23.2 % of the Italian population is 65 or older vs. 19.6 % in Spain). Therefore, the high crude death rates observed in Italy for the period are partly attributable to a great proportion of old inhabitants in its population.

In the case of France, the standardization soothe the crude mortality rates as well, but to a much lesser extent (2 % reduction for each one of the rates). Indeed, and in spite of slight differences, France's population structure by age is much closer to that one of Spain.

	Italy		France	
	Crude	Standardized	Crude	Standardized
EMR	0.86 ‰	0.75 ‰	0.43 ‰	0.42 ‰
<i>MR</i> ^{C19}	0.54 ‰	0.47 ‰	0.43 ‰	0.42 ‰

Table 2. Crude and standardized (on the reference of the population of Spain) excess mortality rate and Covid-19mortality rate for Italy (weeks 10 to 21, 2020) and France (weeks 11 to 22, 2020)

Own elaboration

Having avoided the differences in the structure by age of the population of those countries, the standardized excess mortality rate (*SEMR*) shows high differences between the three countries [Table 3]. While, for the twelve weeks under study, the *SMER* is only 0.42 ‰ in France, it is as high as 1.03 ‰ in Spain (that is, 143 % higher). Italy shows a middle value with 0.75 ‰.

Concerning the deaths officially published as Covid-19 deaths, the differences between the three countries are much slighter: France shows the lowest value of the SMR^{C19} (0.42 ‰) while this rate is equal to 0.47 ‰ in Italy and 0.60 ‰ in Spain.

Moreover, the difference between those two rates (*SMER* and *SMR^{C19}*) varies enormously within the three countries. In France, both rates are practically equal, and more than 99 % of the excess mortality would be attributable to those Covid-19 deaths.

However, Italy and Spain show huge gaps between the *SMER* and the *SMR*^{C19}, and the part of the excess mortality potentially attributable to Covid-19 deaths is only of 62 % in Italy and 59 % in Spain. The standardized balance mortality rate is almost inexistent in France, while it is as high as 0.43 ‰ in Spain and 0.28 ‰ in Italy for the period.

Table 3. Standardized (on the reference of the population of Spain) excess mortality rate, Covid-19 mortality rate and
balance mortality rate in Italy (weeks 10 to 21, 2020), France and Spain (weeks 11 to 22, 2020)

	Italy	France	Spain
SEMR	0.75 ‰	0.42 ‰	1.03 ‰
SMR ^{C19}	0.47 ‰	0.42 ‰	0.60 ‰
SBMR	0.28 ‰	0.00 ‰	0.43 ‰

Own elaboration

4. Discussion

The spatial diffusion of the Covid-19 epidemic in Italy and Spain shows a spread departing from the cities of Milan and Madrid, respectively. Those two cities being the most important economic spots of their respective countries (which leads to a more intense flow of people), they are more likely to be affected by an epidemic in the first place, as shown by Balcan, *et al.* (2009). In the case of Italy, the epidemic disseminates from the Milan area mostly to neighbor provinces while, in Spain, a notable part of the territory shows an important presence of the coronavirus at the beginning of the lockdown. This diffusion matches with the mobility patterns described by Iacus, *et al.* (2020).

This spatial diffusion is well described by our spreading parameter *S* that summarizes the time dynamics of the epidemic. This parameter shows how a rapid initial spread of the coronavirus in Italy and Spain is followed by a stability period further to the implementation of lockdown policies suppressing human mobility. The end of those policies before summer 2020 leads then to the spatial diffusion of the virus and, following the start of the second wave of the epidemic in autumn 2020, the parameter *S* shows a much more homogenous allocation of infections within the aforementioned countries.

Moreover, the *S* parameter shows little dependency on the administrative regions employed. In addition, it is suitable for international comparisons, as it does not depend on the accuracy of the screening in each country, only supposing a similar level of screening for each region within a same country. However, the age structure of each region could have a slight effect on the level of screening, as infections in older people where more easily detected during the first wave, as we can infer from Working group for the surveillance and control of COVID-19 in Spain (2020).

The lack of regional data on Covid-19 cases in France during the first wave of the epidemic entails, however, a limitation to this study, as the dynamics of the epidemic in France could not be described at all.

4.1. Mortality during the epidemic

The analysis of the first wave of the epidemic reveals a consistent increase of mortality in the three countries. This increase is higher for older groups of the population. The population aged under 15 experiences, however, a lower mortality, that could be linked to lockdown policies reducing the number of accidental deaths.

In Italy, excess deaths have been estimated to more than 51,000 for the period running from week 10 until week 21 of 2020. Scortichini, *et al.* (2021) have estimated between 43,984 and 50,362 (95 % eCI) excess deaths for the period between February 15 and May 15. If our method was applied to that period, we would obtain 50,163 excess deaths, thus approaching the Scortichini *et al.* (2021) estimate. Besides, Magnani, Azzolina, Gallo, Ferrante & Gregori (2020) estimate 45,033 excess deaths between March 1 and April 15, while our method applied to that period would give 49,129 excess deaths. Moreover, Kontis, *et al.* (2020) make an estimation of 48,700 excess deaths between mid-February and the end of May, very close to the 50,073 we would obtain with our method.

In France, Fouillet, Pontais & Caserio-Schönemann (2020) estimate the number of excess deaths to more than 25,000 for the months of March to May 2020. This amount is lower than our estimate by 4,000 deaths, but our period of study excludes the first week of March, where excess deaths are -490 according to our method. For that same period, Santé Publique France (2020) estimates between 25,000 and 30,000 excess deaths. In addition, Kontis, *et al.* (2020) estimate 23,700 excess deaths from mid-February to the end of May, some less than the 26,500 that our method estimates for the same period.

In Spain, the *Instituto de Salud Carlos III* (ISCIII) (2020) estimates 44,118 excess deaths between March 13 and May 22, 2020. Our estimate being 48,850 for weeks 11 to 22, it drops to 48,152 when applied to the period studied by ISCIII (2020). In addition, Kontis, *et al.* (2020) estimates 45,800 excess deaths from mid-February to the end of May, very close to the 46,349 obtained by applying our method to that period.

Our excess deaths estimates are thus close to other publications but produce a slight overestimation. This could be due to the very simple employed method (that do not take into account the evolution of the population or its structure), but also, it could be partially attributable to the fact that this publication is submitted six to nine months after Magnani, *et al.* (2020), Fouillet, *et al.* (2020), Santé publique France (SPF) (2020) and ISCIII (2020), thus employing mortality data that are much more complete for spring 2020.

In the absence of information about the medical cause of death, the proportion of those excess deaths attributable to Covid-19 remains unknown. The computed Covid-19 mortality rate and its complement, the balance mortality rate, are ruled by how deaths have been assigned to Covid-19. The balance mortality itself could be partly due directly to undetected Covid-19, but it could also be partially attributable to other pathologies, as mortality and its causes have been also indirectly disturbed by the epidemic and lockdown policies. This balance mortality is very considerable in Spain, quite important in Italy and almost inexistent in France, as Beaney, *et al.* (2020) – who wrongly refers to as "non Covid-19 excess mortality" – has also shown.

Moreover, the magnitude of this balance mortality could have been influenced by healthcare capacity: in countries with a very limited number of hospital beds, the hospital admission of patients presenting Covid-19 symptoms or other pathologies could have been reduced, and certain specific treatments could have been rescheduled, eventually leading to an increase in mortality. Showing a high balance mortality, Italy and Spain had, respectively, 314 and 297 hospital beds available per 100,000 inhabitants in 2018 (Eurostat, 2020), while France had 591 and presents almost no balance mortality. In addition, the definition

of a Covid-19 death employed by Italy and Spain (HSRM, 2020) could have led to an underestimation of Covid-19 deaths and therefore to an increase of the computed balance mortality, while the following of WHO guidelines by France (HRSM, 2020) could have reduced this balance mortality.

5. Conclusions

In this paper, firstly, an alternative analysis of the dynamics of the Covid-19 epidemic has been proposed considering the inaccuracy of public data on the cases of the disease. This analysis in terms of spatial spreading and the introduction of the parameter *S* allow us to describe accurately the spatial dynamics of the epidemic in Italy and Spain without relying on the precision in the screening of the disease. This analysis shows how the epidemic was, as the time of the implementation of lockdown policies, much more widespread within the Spanish territory than within the Italian territory. Moreover, the parameter *S* allows us to track the efficiency of lockdown policies in terms of stopping the spatial diffusion of the coronavirus, as well as the much more homogeneous distribution of the virus at the beginning of the second wave.

Concerning mortality during the epidemic and dealing with all-cause non-individual mortality data, excess mortality has been computed and considered as an indicator of the effect of the epidemic on mortality. This excess mortality has been then split into Covid-19 mortality (according to the official attribution) and balance mortality. All three mortality rates have been standardized by age, allowing us to better compare different countries removing potential effects of the age structure of the population of those countries. Excess mortality has been then shown to be extremely high in Italy, France and Spain during the first wave of the epidemic. Spain presents, by far, the highest age-standardized excess mortality among the three countries have been shown to be much more accentuated than the differences in Covid-19 mortality (as officially attributed). The computed balance mortality is extremely important in Italy and, especially, in Spain, while it is non-existent in France, being possibly related to healthcare capacities in those three countries. The origin of this balance mortality could only be determined by employing individual mortality data including medical cause.

Acknowledgements

I thank Jean-François Léger and Alexandre Avdeev, from University of Paris 1 Panthéon-Sorbonne, for useful discussion and advice.

Appendix 1: data sources

This appendix presents a list of the data sources that have been employed in this study, including details on time and geographical availability, as well as sources and links.

Country	Source - Institution	Details of the dataset	Link
Italy	Andamento Nazionale Covid-19. Presidenza del Consiglio dei Ministri - Dipartimento di Protezione Civile	Daily update on cumulated Covid-19 cases by province. Available from February 24, 2020.	https://github.com/pcm-dpc/ COVID-19/tree/master/dati- province
Spain	Centro Nacional de Epidemiología – Instituto de Salud Carlos III	Daily number of Covid-19 cases by province. Available from January 31, 2020.	https://cnecovid.isciii.es/ covid19/resources/casos_tecnica_ provincia.csv
France*	SI-DEP Data. Santé Publique France	Daily number of Covid-19 cases by province and age class. Only available from May 13, 2020.	https://www.data.gouv.fr/en/ datasets/taux-dincidence-de- lepidemie-de-covid-19/

Table A1. Data source	es on Covid-19 cases
-----------------------	----------------------

* This dataset is not employed for this study

Country	Source - Institution	Details of the dataset	Link
Italy	Andamento Nazionale Covid-19. Presidenza del Consiglio dei Ministri - Dipartimento di Protezione Civile	Daily update on cumulated Covid-19 fatalities by region. Available from February 24, 2020.	https://github.com/pcm-dpc/ COVID-19/tree/master/dati- regioni
Spain	Situación actual. Ministerio de Sanidad, Consumo y Bienestar Social	Daily update on number of cumulated Covid-19 fatalities in the country. Available from January 2020.	https://www.mscbs.gob.es/ profesionales/saludPublica/ <u>ccayes/alertasActual/nCov-China/</u> <u>situacionActual.htm</u>
France	Santé Publique France	Daily update on cumulated number of Covid-19 fatalities in hospitals. Available from March 2, 2020.	https://www.data.gouv.fr/en/ datasets/donnees-relatives-a-
	Ministère des Solidarités et de la Santé	Periodic update on cumulated number of Covid-19 fatalities in nursing homes.	lepidemie-de-covid-19-en-france- vue-densemble/

Table A2. Data sources on Covid-19 deaths

Own elaboration

Table A3	. Data sources	on all-cause deaths
----------	----------------	---------------------

Country	Source - Institution	Details of the dataset	Link
All	The Human Mortality Database – Department of Demography (University of California, Berkeley), Max Planck Institute for Demographic Research	Weekly number of all-cause deaths by age class (2015-2020) in Italy (retrieved from Istat), France (retrieved from Insee) and Spain (retrieved from INE).	https://www.mortality.org/Public/ STMF_DOC/STMFmetadata.pdf

Own elaboration

Table A4. I	Data sources	on population
-------------	--------------	---------------

Country	Source - Institution	Details of the dataset	Link
Italy	Instituto Nazionale di Statistica (Istat)	Total population and population by province and region, by age (1 st January 2020).	http://dati.istat.it/Index. aspx?QueryId=18460⟨=en#
Spain	Instituto Nacional de Estadística (INE)	Population by province and age (1ª January 2020).	https://www.ine.es/jaxi/Tabla. htm?path=/t20/e245/p08/ 10/&file=03002.px&L=0
France	Institut National de Statistique et d'Etudes Economiques (Insee)	Population by age (1 st January 2020).	https://www.insee.fr/fr/ statistiques/ 1892088?sommaire=1912926

Own elaboration

Appendix 2: relative prevalence

This appendix presents the data of the relative prevalence by province in Italy and Spain two weeks before lockdown, the first day of lockdown and two weeks after the implementation of the lockdown.

Province	February 24, 2020 (two weeks before lockdown)	March 9, 2020 (first day of lockdown)	March 23, 2020 (two weeks after lockdown)
Torino	0.3	0.3	0.9
Vercelli	0.0	0.5	1.5
Novara	0.0	0.3	1.1
Cuneo	0.0	0.1	0.6
Asti	0.0	1.9	1.0
Alessandria	0.0	1.1	1.9
Valle d'Aosta	0.0	0.9	3.0
Imperia	0.0	0.4	0.7
Savona	0.7	0.9	0.7
Genova	0.0	0.3	0.8
La Spezia	0.0	0.5	0.5
Varese	0.0	0.4	0.5
Como	0.0	0.5	0.9
Sondrio	1.1	0.3	1.1
Milano	0.5	1.1	1.6
Bergamo	3.1	7.9	5.6
Brescia	0.0	4.1	4.5
Pavia	9.5	3.9	2.6
Cremona	28.6	18.2	7.9
Mantova	0.0	1.8	2.3
Bolzano/Bozen	0.4	0.1	1.3
Trento	0.0	0.4	1.8
Verona	0.0	0.6	1.1
Vicenza	0.0	0.4	0.8
Belluno	0.0	1.0	1.2
Treviso	0.2	1.1	1.1
Venezia	1.6	1.1	0.9
Padova	6.2	2.1	1.4
Rovigo	0.0	0.2	0.3
Udine	0.0	0.3	0.7
Gorizia	0.0	0.3	0.4
Trieste	0.0	0.8	1.3
Piacenza	12.1	14.9	6.4
Parma	1.7	4.4	2.9
Reggio nell'Emilia	0.0	1.4	2.5
Modena	0.8	1.2	1.0
Bologna	0.0	0.6	0.8
Ferrara	0.0	0.1	0.5

Table A5. Value of *RPrev* in all of Italy's provinces on February 24, March 9 and March 23, 2020 (bold when *RPrev* > 1.5)

Methodological element	nts for the	comparative	analysis of t	he first wa	ive of the Covi	d-19 epidemic in	France, Italy, and Spain
------------------------	-------------	-------------	---------------	-------------	-----------------	------------------	--------------------------

Ravenna	0.0	0.3	0.9
Forlì-Cesena	0.0	0.3	0.9
Pesaro e Urbino	0.0	4.9	3.6
Ancona	0.0	1.0	1.5
Macerata	0.0	0.2	1.0
Ascoli Piceno	0.0	0.0	0.3
Massa-Carrara	0.0	1.0	1.4
Lucca	0.0	0.6	0.9
Pistoia	0.7	0.4	0.8
Firenze	0.2	0.4	0.5
Livorno	0.0	0.2	0.4
Pisa	0.0	0.3	0.6
Arezzo	0.0	0.3	0.6
Siena	0.0	0.8	0.6
Grosseto	0.0	0.2	0.6
Perugia	0.0	0.1	0.6
Terni	0.0	0.5	0.6
Viterbo	0.0	0.0	0.3
Rieti	0.0	0.0	0.2
Roma	0.1	0.1	0.3
Latina	0.0	0.1	0.3
Frosinone	0.0	0.0	0.2
Caserta	0.0	0.2	0.1
Benevento	0.0	0.1	0.0
Napoli	0.0	0.1	0.2
Avellino	0.0	0.1	0.3
Salerno	0.0	0.1	0.2
ĽAquila	0.0	0.1	0.1
Teramo	0.0	0.1	0.4
Pescara	0.0	0.3	1.1
Chieti	0.0	0.1	0.3
Campobasso	0.0	0.5	0.2
Foggia	0.0	0.3	0.4
Bari	0.0	0.0	0.2
Taranto	0.0	0.0	0.1
Brindisi	0.0	0.1	0.3
Lecce	0.0	0.1	0.2
Potenza	0.0	0.0	0.2
Matera	0.0	0.1	0.1
Cosenza	0.0	0.0	0.1
Catanzaro	0.0	0.1	0.1
Reggio Calabria	0.0	0.0	0.2
Trapani	0.0	0.0	0.1
Palermo	0.5	0.0	0.1

Messina	0.0	0.0	0.2
Agrigento	0.0	0.0	0.1
	0.0		
Caltanissetta		0.0	0.1
Enna	0.0	0.0	0.3
Catania	0.0	0.1	0.2
Ragusa	0.0	0.0	0.0
Siracusa	0.0	0.0	0.1
Sassari	0.0	0.0	0.5
Nuoro	0.0	0.1	0.1
Cagliari	0.0	0.2	0.1
Pordenone	0.0	0.0	0.5
Isernia	0.0	0.0	0.0
Oristano	0.0	0.0	0.0
Biella	0.0	0.7	1.4
Lecco	0.0	1.4	2.7
Lodi	104.7	28.7	7.7
Rimini	0.6	3.4	3.0
Prato	0.0	0.1	0.5
Crotone	0.0	0.0	0.4
Vibo Valentia	0.0	0.1	0.1
Verbano-Cusio-Ossola	0.0	0.5	1.2
Monza e della Brianza	0.7	0.5	1.2
Fermo	0.0	0.2	0.7
Barletta-Andria-Trani	0.0	0.1	0.1
Sud Sardegna	0.0	0.0	0.0

Own elaboration

Table A6. Value of *RPrev* in all of Spain's provinces on March 1, March 15 and March 29, 2020 (bold when *RPrev* > 1.5).

Province	March 1, 2020 (two weeks before lockdown)	March 15, 2020 (first day of lockdown)	March 29, 2020 (two weeks after lockdown)
Alicante	0.8	0.6	0.5
Albacete	0.9	1.8	2.0
Almería	0.0	0.1	0.2
Ávila	1.3	1.5	2.2
Barcelona	1.0	1.2	1.3
Badajoz	0.3	0.2	0.3
Vizcaya	0.9	0.9	1.2
Burgos	1.4	1.1	1.1
La Coruña	0.2	0.5	0.6
Cádiz	0.1	0.2	0.2
Cáceres	1.2	1.0	1.3
Ceuta	0.4	0.2	0.4
Córdoba	0.1	0.3	0.4
Ciudad Real	1.3	2.7	3.0

Castellón	0.4	0.5	0.5
Cuenca	0.5	1.7	1.9
Las Palmas	0.1	0.2	0.2
Gerona	0.6	0.7	0.8
Granada	0.2	0.4	0.6
Guadalajara	1.6	1.5	1.4
Huelva	0.1	0.1	0.2
Huesca	0.6	0.3	0.6
Jaén	0.3	0.4	0.5
Lérida	0.3	0.5	0.8
León	0.7	0.6	1.1
Logroño	3.7	2.6	2.6
Lugo	0.3	0.4	0.5
Madrid	3.2	2.8	2.2
Málaga	0.7	0.5	0.4
Melilla	0.0	0.4	0.3
Murcia	0.3	0.4	0.4
Navarra	1.2	1.9	2.0
Asturias	0.1	0.4	0.4
Orense	0.8	0.8	1.0
Palencia	0.8	0.5	1.1
Baleares	0.3	0.3	0.4
Pontevedra	0.1	0.4	0.6
Cantabria	0.3	0.4	0.7
Salamanca	0.3	1.3	2.1
Sevilla	0.3	0.2	0.3
Segovia	1.5	2.7	3.8
Soria	1.8	3.2	3.9
Guipúzcoa	0.1	0.5	0.6
Tarragona	0.2	0.3	0.4
Teruel	0.4	0.5	0.8
Santa Cruz de Tenerife	0.6	0.4	0.3
Toledo	0.8	1.1	1.3
Valencia	0.7	0.6	0.5
Valladolid	0.6	0.8	1.2
Álava	5.7	3.1	2.4
Zaragoza	0.5	0.5	0.8
Zamora	0.3	0.6	0.8

Methodological elements for the comparative analysis of the first wave of the Covid-19 epidemic in France, Italy, and Spain

Own elaboration

References

Balcan, D., Colizza, V., Goncalves, B., Hu, H., Ramasco, J. J., & Vespignani, A. (2009). Multiscale mobility networks and the spatial spreading of infectious diseases. *Proceedings of the National Academy of Sciences*, 106(51), 21484–21489. <u>https://doi.org/10.1073/pnas.0906910106</u>

- Beaney, T., Clarke, J. M., Jain, V., Golestaneh, A. K., Lyons, G., Salman, D., & Majeed, A. (2020). Excess mortality: the gold standard in measuring the impact of COVID-19 worldwide?. *Journal of the Royal Society of Medicine*, 113(9), 329–334. https://doi.org/10.1177/0141076820956802
- Bernard Stoecklin, S., Rolland, P., Silue, Y., Mailles, A., Campese, C., Simondon, A., ... & Tabaï, A. (2020). First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. *Eurosurveillance*, 25(6). <u>https://doi.org/10.2807/1560-7917</u>. es.2020.25.6.2000094
- Eurostat (2020). *Hospital beds* (TPS00046) [Data set]. Retrieved from <u>https://ec.europa.eu/eurostat/</u> product?code=HLTH_RS_BDS&mode=view
- Fouillet, A., Pontais, I., & Caserio-Schönemann, C. (2020). Excess all-cause mortality during the first wave of the COVID-19 epidemic in France, March to May 2020. *Eurosurveillance*, 25(34). <u>https://doi.org/10.2807/1560-7917.es.2020.25.34.2001485</u>
- Giorgi Rossi, P., Marino, M., Formisano, D., Venturelli, F., Vicentini, M., & Grilli, R. (2020). Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy. *PLOS ONE*, 15(8), e0238281. <u>https://doi.org/10.1371/journal.pone.0238281</u>
- Health System Response Monitor (HRSM) (2020, June 4). *How comparable is COVID-19 mortality across countries*? [Press release]. Retrieved from <u>https://analysis.covid19healthsystem.org/index.php/2020/06/04/how-comparable-is-covid-19-mortality-across-countries/</u>
- Hoffmann, C., & Wolf, E. (2020). SARS-CoV-2 seroprevalence in Spain. *The Lancet*, 396(10261), 1484. https://doi.org/10.1016/s0140-6736(20)32272-8
- Iacus, S. M., Santamaria, C., Sermi, F., Spyratos, S., Tarchi, D., & Vespe, M. (2020). Human mobility and COVID-19 initial dynamics. *Nonlinear Dynamics*, 101(3), 1901–1919. <u>https://doi.org/10.1007/ s11071-020-05854-6</u>
- Instituto de Salud Carlos III (ISCIII) (2020, July 29). Vigilancia de los excesos de mortalidad por todas las causas. MoMo. Situación a 19 de julio de 2020 [Press release]. Retrieved from <u>https://www.isciii.</u> <u>es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/MoMo/</u> <u>Documents/informesMoMo2020/MoMo_Situacion%20a%2019%20de%20julio_CNE.pdf</u>
- Kaeuffer, C., Le Hyaric, C., Fabacher, T., Mootien, J., Dervieux, B., Ruch, Y., ... & Danion, F. (2020). Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. *Eurosurveillance*, 25(48). <u>https://doi.org/10.2807/1560-7917.ES.2020.25.48.2000895</u>
- Kontis, V., Bennett, J. E., Rashid, T., Parks, R. M., Pearson-Stuttard, J., Guillot, M., ... & Ezzati, M. (2020).
 Magnitude, demographics and dynamics of the effect of the first wave of the COVID-19 pandemic on all-cause mortality in 21 industrialized countries. *Nature Medicine*, 26(12), 1919–1928. <u>https://doi.org/10.1038/s41591-020-1112-0</u>
- Magnani, C., Azzolina, D., Gallo, E., Ferrante, D., & Gregori, D. (2020). How Large Was the Mortality Increase Directly and Indirectly Caused by the COVID-19 Epidemic? An Analysis on All-Causes Mortality Data in Italy. *International Journal of Environmental Research and Public Health*, 17(10), 3452. <u>https://doi.org/10.3390/ijerph17103452</u>
- Pearce, N., Lawlor, D. A., & Brickley, E. B. (2020). Comparisons between countries are essential for the control of COVID-19. *International journal of epidemiology*, 49(4), 1059–1062. <u>https://doi.org/10.1093/ ije/dyaa108</u>
- Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., ... & Vázquez de la Villa, A. (2020). Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, populationbased seroepidemiological study. *The Lancet*, 396(10250), 535–544. <u>https://doi.org/10.1016/s0140-6736(20)31483-5</u>
- Roques, L., Bonnefon, O., Baudrot, V., Soubeyrand, S., & Berestycki, H. (2020). A parsimonious approach for spatial transmission and heterogeneity in the COVID-19 propagation. *Royal Society Open Science*, 7(12), 201382. <u>https://doi.org/10.1098/rsos.201382</u>
- Santé Publique France (SPF) (2020, July). Surveillance de la mortalité au cours de l'épidémie de Covid-19 du 2 Mars au 31 Mai en France [Press release]. Retrieved from <u>https://www.santepubliquefrance.fr/</u> <u>maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/</u> <u>rapport-synthese/surveillance-de-la-mortalite-au-cours-de-l-epidemie-de-covid-19-du-2-mars-au-</u> <u>31-mai-2020-en-france</u>

- Scortichini, M., Schneider Dos Santos, R., De' Donato, F., De Sario, M., Michelozzi, P., Davoli, M., ... & Gasparrini, A. (2021). Excess mortality during the COVID-19 outbreak in Italy: a two-stage interrupted time-series analysis. *International journal of epidemiology*, 49(6), 1909–1917. <u>https://doi.org/10.1093/ije/dyaa169</u>
- Spiteri, G., Fielding, J., Diercke, M., Campese, C., Enouf, V., Gaymard, A., ... & Ciancio, B. C. (2020). First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. Eurosurveillance, 25(9). <u>https://doi.org/10.2807/1560-7917.es.2020.25.9.2000178</u>
- Stefanelli, P., Bella, A., Fedele, G., Pancheri, S., Leone, P., Vacca, P., ... & Ferro, A. (2020). Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study. *Clinical Microbiology and Infection*. https://doi.org/10.1016/j.cmi.2020.11.013
- Working group for the surveillance and control of COVID-19 in Spain (2020). The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. *Eurosurveillance*, 25(50). https://doi.org/10.2807/1560-7917.es.2020.25.50.2001431